Editorial: New frontiers in "bladder sparing" treatments for high risk NMIBC.
作者信息
Hurle Rodolfo, Lazzeri Massimo
机构信息
Department of Urology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Italy.
出版信息
Front Oncol. 2023 Jan 11;12:1118940. doi: 10.3389/fonc.2022.1118940. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: New frontiers in "bladder sparing" treatments for high risk NMIBC.社论：高危非肌层浸润性膀胱癌“保留膀胱”治疗的新前沿
Front Oncol. 2023 Jan 11;12:1118940. doi: 10.3389/fonc.2022.1118940. eCollection 2022.
2
Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.前瞻性评估膀胱影像报告和数据系统（VI-RADS）及其对高危非肌肉浸润性膀胱癌患者重复经尿道切除术候选者管理的临床影响。
Eur Urol. 2020 Jan;77(1):101-109. doi: 10.1016/j.eururo.2019.09.029. Epub 2019 Nov 5.
3
Multi-country clinical practice patterns, including use of biomarkers, among physicians' treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).多国临床实践模式，包括生物标志物的使用，在医生治疗卡介苗无反应性非肌肉浸润性膀胱癌（NMIBC）中的应用。
BMC Urol. 2022 Feb 26;22(1):27. doi: 10.1186/s12894-022-00959-z.
4
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.经卡介苗膀胱内灌注后非肌层浸润性膀胱癌的膀胱保留治疗疗效的系统评价
Eur Urol. 2020 Sep;78(3):387-399. doi: 10.1016/j.eururo.2020.02.012. Epub 2020 Mar 4.
5
Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.BUB1 对预测非肌肉浸润性膀胱癌进展的预后价值。
Int J Mol Sci. 2021 Nov 25;22(23):12756. doi: 10.3390/ijms222312756.
6
The clinical and prognostic value of miR-9 gene expression in Tunisian patients with bladder cancer.miR-9 基因表达在突尼斯膀胱癌患者中的临床和预后价值。
Mol Biol Rep. 2019 Oct;46(5):4743-4750. doi: 10.1007/s11033-019-04920-6. Epub 2019 Jun 18.
7
Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.卡介苗无应答非肌肉浸润性膀胱癌的新兴治疗选择。
Curr Opin Support Palliat Care. 2022 Mar 1;16(1):48-53. doi: 10.1097/SPC.0000000000000587.
8
Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.针对卡介苗无应答性非肌肉浸润性膀胱癌的新兴治疗方法。
Investig Clin Urol. 2021 Jul;62(4):361-377. doi: 10.4111/icu.20200602. Epub 2021 May 27.
9
The efficacy and reliability of VI-RADS in determining candidates for repeated transurethral resection in patients with high-risk non-muscle invasive bladder cancer.VI-RADS 在确定高危非肌肉浸润性膀胱癌患者重复经尿道膀胱肿瘤切除术候选人中的疗效和可靠性。
Int J Clin Pract. 2021 Sep;75(9):e14584. doi: 10.1111/ijcp.14584. Epub 2021 Jul 9.
10
Chlorin e6-polyvinylpyrrolidone mediated photodynamic therapy--A potential bladder sparing option for high risk non-muscle invasive bladder cancer.氯乙啶-聚乙烯吡咯烷酮介导的光动力疗法——高危非肌肉浸润性膀胱癌的膀胱保留潜力选择。
Photodiagnosis Photodyn Ther. 2010 Dec;7(4):213-20. doi: 10.1016/j.pdpdt.2010.08.005. Epub 2010 Sep 29.
本文引用的文献
1
Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start.Oncofid-P-B：一种用于治疗卡介苗无应答的膀胱癌原位癌（CIS）的新型治疗方法：治疗开始后 15 个月的前瞻性欧洲多中心研究结果。
Urol Oncol. 2022 Jan;40(1):11.e9-11.e15. doi: 10.1016/j.urolonc.2021.07.007. Epub 2021 Oct 12.
2
A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases.四抗体免疫组织化学组合可区分尿路上皮癌的临床病理簇，并显示原发肿瘤与淋巴结转移之间具有高度一致性。
Virchows Arch. 2021 Apr;478(4):637-645. doi: 10.1007/s00428-020-02951-0. Epub 2020 Oct 30.
3
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer.肌肉浸润性膀胱癌的共识分子分类。
Eur Urol. 2020 Apr;77(4):420-433. doi: 10.1016/j.eururo.2019.09.006. Epub 2019 Sep 26.
4
Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System).膀胱癌的多参数磁共振成像：VI-RADS（膀胱成像-报告和数据系统）的制定。
Eur Urol. 2018 Sep;74(3):294-306. doi: 10.1016/j.eururo.2018.04.029. Epub 2018 May 10.
5
Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer.不同分期系统在首次和二次经尿道膀胱肿瘤切除术治疗 T1 高分级膀胱癌患者中的可行性和临床作用。
Eur Urol Focus. 2018 Jan;4(1):87-93. doi: 10.1016/j.euf.2016.06.004. Epub 2016 Jun 15.
6
Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.使用欧洲癌症研究与治疗组织（EORTC）风险表预测Ta T1期膀胱癌个体患者的复发和进展：来自七项EORTC试验的2596例患者的综合分析
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. doi: 10.1016/j.eururo.2005.12.031. Epub 2006 Jan 17.
Zotero 插件